Citadel Advisors
BLCM

Citadel Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Citadel Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,386
Closed -$13K – 14017
2022
Q2 		$13K Buy
+11,386
New +$17.2K ﹤0.01% 12534
2021
Q4 		– Sell
-33,252
Closed -$97K – 15158
2021
Q3 		$97K Sell
33,252
-365
-1% -$1.11K ﹤0.01% 12921
2021
Q2 		$111K Sell
33,617
-20,430
-38% -$65.6K ﹤0.01% 12828
2021
Q1 		$203K Buy
54,047
+27,077
+100% +$118K ﹤0.01% 11675
2020
Q4 		$95K Buy
+26,970
New +$114K ﹤0.01% 10254
2020
Q1 		– Sell
-1,162
Closed -$15K – 10386
2019
Q4 		$15K Buy
+1,162
New +$10.7K ﹤0.01% 8980
2019
Q3 		– Sell
-11,685
Closed -$153K – 9932
2019
Q2 		$199K Buy
11,685
+5,694
+95% +$154K ﹤0.01% 8195
2019
Q1 		$201K Buy
5,991
+1,034
+21% +$34.6K ﹤0.01% 8207
2018
Q4 		$145K Sell
4,957
-1,800
-27% -$79.9K ﹤0.01% 8078
2018
Q3 		$416K Sell
6,757
-10,473
-61% -$709K ﹤0.01% 6998
2018
Q2 		$1.27M Sell
17,230
-942
-5% -$73.4K ﹤0.01% 4810
2018
Q1 		$1.19M Buy
18,172
+8,528
+88% +$644K ﹤0.01% 4533
2017
Q4 		$811K Sell
9,644
-10,960
-53% -$1.07M ﹤0.01% 4953
2017
Q3 		$2.38M Buy
20,604
+14,105
+217% +$1.48M ﹤0.01% 3212
2017
Q2 		$759K Buy
6,499
+2,956
+83% +$367K ﹤0.01% 4519
2017
Q1 		$438K Buy
+3,543
New +$464K ﹤0.01% 5243
2016
Q2 		– Sell
-1,589
Closed -$177K – 7573
2016
Q1 		$149K Sell
1,589
-1,053
-40% -$115K ﹤0.01% 5832
2015
Q4 		$536K Sell
2,642
-59,381
-96% -$10.6M ﹤0.01% 4385
2015
Q3 		$9.01M Buy
62,023
+17,074
+38% +$3.13M 0.01% 1429
2015
Q2 		$9.56M Buy
44,949
+21,424
+91% +$5.25M 0.01% 1504
2015
Q1 		$5.45M Sell
23,525
-10,328
-31% -$2.5M 0.01% 1956
2014
Q4 		$7.8M Buy
+33,853
New +$7.26M 0.01% 1591

Other funds holding BLCM

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's BLCM Position: Q3 2022 in Review

Citadel Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2022, closing a stake of 11,386 shares — an estimated $13K sold.

Citadel Advisors first reported a position in BLCM in Q4 2014 and held it in 22 quarters. The position peaked at $9.56M in Q2 2015. 28 funds tracked by Wall St. Rank hold BLCM as of Q3 2022.

  • Citadel Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 11,386 Bellicum Pharmaceuticals, Inc. shares in Q3 2022, an estimated $13K.
  • Citadel Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 22 quarters.
  • Citadel Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $9.56M in Q2 2015.
  • 28 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.